Summary

The global Human Hyperimmune Globulins market size was US$ 2334 million in 2025 and is forecast to reach a readjusted size of US$ 3587 million by 2032 with a CAGR of 6.4% during the forecast period 2026-2032.
Hyperimmune Globulin is a highly concentrated immunoglobulin containing high levels of specific antibodies used for passive immunotherapy. It is usually extracted from the plasma of recovered patients who have been infected with a specific pathogen, so these people have produced high levels of antibodies against the pathogen.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
The global Human Hyperimmune Globulins market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
CSL Behring
Grifols
Biotest
Kedrion
Emergent
Kamada
CNBG
Hualan Bio
Shanghai RAAS
CBPO
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immuneglobulins
Rabies Immuneglobulins
Tetanus Toxin Immuneglobulins
Rho(D) Immune Globulin
Cytomegalovirus Immune Globulin
Varicella-Zoster Immune Globulin
Others
Segment by Application
Government Institutions
Private Sector
Others
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market
North America
Europe
China
Australia
Chapter Outline
Chapter 1: Report scope, segment-level executive summary (by Type, by Application) and market evolution across the short, mid and long term
Chapter 2: Quantitative analysis of Human Hyperimmune Globulins sales and revenue at global, regional, and country levels, highlighting market size and growth potential by region
Chapter 3: Competitive landscape of Human Hyperimmune Globulins manufacturers (sales, revenue, pricing, market share, industry rankings, and M&A / expansion plans)
Chapter 4: by Type-based segmentation analysis (sales, revenue, pricing, and growth potential) to identify blue-ocean product segments
Chapter 5: by Application-based segmentation analysis (sales, revenue, pricing, and growth potential) to uncover high-value downstream markets
Chapter 6: Regional breakdown by company, customer, by Type and by Application (sales, revenue, and pricing for each segment)
Chapter 7: Key manufacturer profiles –company overview, Human Hyperimmune Globulins product descriptions and specifications, revenue, gross margins, and recent developments
Chapter 8: Industry chain analysis – upstream raw materials, manufacturing links, and downstream application sectors
Chapter 9: Sales channels and distributor analysis – routes to market and key customer interfaces
Chapter 10: Market dynamics – trends, drivers, restraints, risks for manufacturers, and the impact of relevant industry policies
Chapter 11: Key findings, main takeaways, and overall conclusions of the report.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Human Hyperimmune Globulins value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Human Hyperimmune Globulins Product Scope
1.2 Human Hyperimmune Globulins by Type
1.2.1 Global Human Hyperimmune Globulins Sales by Type (2021, 2025 & 2032)
1.2.2 Hepatitis B Immuneglobulins
1.2.3 Rabies Immuneglobulins
1.2.4 Tetanus Toxin Immuneglobulins
1.2.5 Rho(D) Immune Globulin
1.2.6 Cytomegalovirus Immune Globulin
1.2.7 Varicella-Zoster Immune Globulin
1.2.8 Others
1.3 Human Hyperimmune Globulins by Application
1.3.1 Global Human Hyperimmune Globulins Sales Comparison by Application (2021, 2025 & 2032)
1.3.2 Government Institutions
1.3.3 Private Sector
1.3.4 Others
1.4 Global Human Hyperimmune Globulins Market Estimates and Forecasts (2021-2032)
1.4.1 Global Human Hyperimmune Globulins Market Size (Value) and Growth Rate (2021-2032)
1.4.2 Global Human Hyperimmune Globulins Market Size (Volume) and Growth Rate (2021-2032)
1.4.3 Global Human Hyperimmune Globulins Price Trends (2021-2032)
1.5 Assumptions and Limitations
2 Market Size and Prospects by Region
2.1 Global Human Hyperimmune Globulins Market Size by Region: 2021 VS 2025 VS 2032
2.2 Global Human Hyperimmune Globulins Historical Market Scenario by Region (2021-2026)
2.2.1 Global Human Hyperimmune Globulins Sales Market Share by Region (2021-2026)
2.2.2 Global Human Hyperimmune Globulins Revenue Market Share by Region (2021-2026)
2.3 Global Human Hyperimmune Globulins Market Estimates and Forecasts by Region (2027-2032)
2.3.1 Global Human Hyperimmune Globulins Sales Estimates and Forecasts by Region (2027-2032)
2.3.2 Global Human Hyperimmune Globulins Revenue Forecast by Region (2027-2032)
2.4 Major Regions and Emerging Market Analysis
2.4.1 North America Human Hyperimmune Globulins Market Size and Prospects (2021-2032)
2.4.2 Europe Human Hyperimmune Globulins Market Size and Prospects (2021-2032)
2.4.3 China Human Hyperimmune Globulins Market Size and Prospects (2021-2032)
2.4.4 Australia Human Hyperimmune Globulins Market Size and Prospects (2021-2032)
3 Global Market Size by Type
3.1 Global Human Hyperimmune Globulins Historical Market Review by Type (2021-2026)
3.1.1 Global Human Hyperimmune Globulins Sales by Type (2021-2026)
3.1.2 Global Human Hyperimmune Globulins Revenue by Type (2021-2026)
3.1.3 Global Human Hyperimmune Globulins Average Price by Type (2021-2026)
3.2 Global Human Hyperimmune Globulins Market Estimates and Forecasts by Type (2027-2032)
3.2.1 Global Human Hyperimmune Globulins Sales Forecast by Type (2027-2032)
3.2.2 Global Human Hyperimmune Globulins Revenue Forecast by Type (2027-2032)
3.2.3 Global Human Hyperimmune Globulins Price Forecast by Type (2027-2032)
3.3 Representative Players for Different Types of Human Hyperimmune Globulins
4 Global Market Size by Application
4.1 Global Human Hyperimmune Globulins Historical Market Review by Application (2021-2026)
4.1.1 Global Human Hyperimmune Globulins Sales by Application (2021-2026)
4.1.2 Global Human Hyperimmune Globulins Revenue by Application (2021-2026)
4.1.3 Global Human Hyperimmune Globulins Average Price by Application (2021-2026)
4.2 Global Human Hyperimmune Globulins Market Estimates and Forecasts by Application (2027-2032)
4.2.1 Global Human Hyperimmune Globulins Sales Forecast by Application (2027-2032)
4.2.2 Global Human Hyperimmune Globulins Revenue Forecast by Application (2027-2032)
4.2.3 Global Human Hyperimmune Globulins Price Forecast by Application (2027-2032)
4.3 New Sources of Growth in Human Hyperimmune Globulins Applications
5 Competition Landscape by Players
5.1 Global Human Hyperimmune Globulins Sales by Player (2021-2026)
5.2 Global Top Human Hyperimmune Globulins Players by Revenue (2021-2026)
5.3 Global Human Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3), based on Human Hyperimmune Globulins revenue as of 2025
5.4 Global Human Hyperimmune Globulins Average Price by Company (2021-2026)
5.5 Global Key Manufacturers of Human Hyperimmune Globulins, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Human Hyperimmune Globulins, Product Type & Application
5.7 Global Key Manufacturers of Human Hyperimmune Globulins, Date of Entry into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Regional Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Human Hyperimmune Globulins Sales by Company
6.1.1.1 North America Human Hyperimmune Globulins Sales by Company (2021-2026)
6.1.1.2 North America Human Hyperimmune Globulins Revenue by Company (2021-2026)
6.1.2 North America Human Hyperimmune Globulins Sales Breakdown by Type (2021-2026)
6.1.3 North America Human Hyperimmune Globulins Sales Breakdown by Application (2021-2026)
6.1.4 North America Human Hyperimmune Globulins Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Human Hyperimmune Globulins Sales by Company
6.2.1.1 Europe Human Hyperimmune Globulins Sales by Company (2021-2026)
6.2.1.2 Europe Human Hyperimmune Globulins Revenue by Company (2021-2026)
6.2.2 Europe Human Hyperimmune Globulins Sales Breakdown by Type (2021-2026)
6.2.3 Europe Human Hyperimmune Globulins Sales Breakdown by Application (2021-2026)
6.2.4 Europe Human Hyperimmune Globulins Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Human Hyperimmune Globulins Sales by Company
6.3.1.1 China Human Hyperimmune Globulins Sales by Company (2021-2026)
6.3.1.2 China Human Hyperimmune Globulins Revenue by Company (2021-2026)
6.3.2 China Human Hyperimmune Globulins Sales Breakdown by Type (2021-2026)
6.3.3 China Human Hyperimmune Globulins Sales Breakdown by Application (2021-2026)
6.3.4 China Human Hyperimmune Globulins Major Customers
6.3.5 China Market Trends and Opportunities
6.4 Australia Market: Players, Segments, Downstream and Major Customers
6.4.1 Australia Human Hyperimmune Globulins Sales by Company
6.4.1.1 Australia Human Hyperimmune Globulins Sales by Company (2021-2026)
6.4.1.2 Australia Human Hyperimmune Globulins Revenue by Company (2021-2026)
6.4.2 Australia Human Hyperimmune Globulins Sales Breakdown by Type (2021-2026)
6.4.3 Australia Human Hyperimmune Globulins Sales Breakdown by Application (2021-2026)
6.4.4 Australia Human Hyperimmune Globulins Major Customers
6.4.5 Australia Market Trends and Opportunities
7 Company Profiles and Key Figures
7.1 CSL Behring
7.1.1 CSL Behring Company Information
7.1.2 CSL Behring Business Overview
7.1.3 CSL Behring Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.1.4 CSL Behring Human Hyperimmune Globulins Products Offered
7.1.5 CSL Behring Recent Development
7.2 Grifols
7.2.1 Grifols Company Information
7.2.2 Grifols Business Overview
7.2.3 Grifols Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.2.4 Grifols Human Hyperimmune Globulins Products Offered
7.2.5 Grifols Recent Development
7.3 Biotest
7.3.1 Biotest Company Information
7.3.2 Biotest Business Overview
7.3.3 Biotest Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.3.4 Biotest Human Hyperimmune Globulins Products Offered
7.3.5 Biotest Recent Development
7.4 Kedrion
7.4.1 Kedrion Company Information
7.4.2 Kedrion Business Overview
7.4.3 Kedrion Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.4.4 Kedrion Human Hyperimmune Globulins Products Offered
7.4.5 Kedrion Recent Development
7.5 Emergent
7.5.1 Emergent Company Information
7.5.2 Emergent Business Overview
7.5.3 Emergent Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.5.4 Emergent Human Hyperimmune Globulins Products Offered
7.5.5 Emergent Recent Development
7.6 Kamada
7.6.1 Kamada Company Information
7.6.2 Kamada Business Overview
7.6.3 Kamada Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.6.4 Kamada Human Hyperimmune Globulins Products Offered
7.6.5 Kamada Recent Development
7.7 CNBG
7.7.1 CNBG Company Information
7.7.2 CNBG Business Overview
7.7.3 CNBG Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.7.4 CNBG Human Hyperimmune Globulins Products Offered
7.7.5 CNBG Recent Development
7.8 Hualan Bio
7.8.1 Hualan Bio Company Information
7.8.2 Hualan Bio Business Overview
7.8.3 Hualan Bio Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.8.4 Hualan Bio Human Hyperimmune Globulins Products Offered
7.8.5 Hualan Bio Recent Development
7.9 Shanghai RAAS
7.9.1 Shanghai RAAS Company Information
7.9.2 Shanghai RAAS Business Overview
7.9.3 Shanghai RAAS Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.9.4 Shanghai RAAS Human Hyperimmune Globulins Products Offered
7.9.5 Shanghai RAAS Recent Development
7.10 CBPO
7.10.1 CBPO Company Information
7.10.2 CBPO Business Overview
7.10.3 CBPO Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.10.4 CBPO Human Hyperimmune Globulins Products Offered
7.10.5 CBPO Recent Development
7.11 Sichuan Yuanda Shuyang
7.11.1 Sichuan Yuanda Shuyang Company Information
7.11.2 Sichuan Yuanda Shuyang Business Overview
7.11.3 Sichuan Yuanda Shuyang Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.11.4 Sichuan Yuanda Shuyang Human Hyperimmune Globulins Products Offered
7.11.5 Sichuan Yuanda Shuyang Recent Development
7.12 ADMA Biologics
7.12.1 ADMA Biologics Company Information
7.12.2 ADMA Biologics Business Overview
7.12.3 ADMA Biologics Human Hyperimmune Globulins Sales, Revenue and Gross Margin (2021-2026)
7.12.4 ADMA Biologics Human Hyperimmune Globulins Products Offered
7.12.5 ADMA Biologics Recent Development
8 Human Hyperimmune Globulins Manufacturing Cost Analysis
8.1 Human Hyperimmune Globulins Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Human Hyperimmune Globulins
8.4 Human Hyperimmune Globulins Industrial Chain Analysis
9 Marketing Channels, Distributors and Customers
9.1 Marketing Channels
9.2 Human Hyperimmune Globulins Distributors List
9.3 Human Hyperimmune Globulins Customers
10 Human Hyperimmune Globulins Market Dynamics
10.1 Human Hyperimmune Globulins Industry Trends
10.2 Human Hyperimmune Globulins Market Drivers
10.3 Human Hyperimmune Globulins Market Challenges
10.4 Human Hyperimmune Globulins Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer